KR890014124A - Il-6 분자의 사용방법 - Google Patents

Il-6 분자의 사용방법 Download PDF

Info

Publication number
KR890014124A
KR890014124A KR1019890002617A KR890002617A KR890014124A KR 890014124 A KR890014124 A KR 890014124A KR 1019890002617 A KR1019890002617 A KR 1019890002617A KR 890002617 A KR890002617 A KR 890002617A KR 890014124 A KR890014124 A KR 890014124A
Authority
KR
South Korea
Prior art keywords
molecule
manufacture
molecules
treatment
bone
Prior art date
Application number
KR1019890002617A
Other languages
English (en)
Inventor
호노레 엠. 페엔 예안
울리히트레크젤
Original Assignee
예안 크라메르.한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888805231A external-priority patent/GB8805231D0/en
Priority claimed from GB888810899A external-priority patent/GB8810899D0/en
Application filed by 예안 크라메르.한스 루돌프 하우스, 산도즈 리미티드 filed Critical 예안 크라메르.한스 루돌프 하우스
Publication of KR890014124A publication Critical patent/KR890014124A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음.

Description

IL-6 분자의 사용방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 골흡수억제에 적합한 의약제조에 있어서의 IL-6 분자의 사용방법.
  2. 골형성 증진에 적합한 의약제조에 있어서의 IL-6 분자의 사용방법.
  3. 골다공증치료에 적합한 의약제조에 있어서의 IL-6 분자의 사용방법.
  4. 골관절염치료에 적합한 의약제조에 있어서의 IL-6 분자의 사용방법.
  5. 하기의 질병중 적어도 하나를 치료하는데 적합한 의약제조에 있어서의 IL-6 분자의 사용방법 ; 골의 파게트병, 골악성 종양으로인한 골분해, 골연화증 골의 다발성 골수종, 골형성 부전증 및 골수염.
  6. 골의 다발성골수종 치료에 적합한 의약제조에 있어서의 IL-6 분자의 사용방법.
  7. 과칼슘혈증치료에 적합한 의약제조에 있어서의 IL-6 분자의 사용방법.
  8. 제1항 내지 제7항중 어느 한항에 있어서, 상기 IL-6 분자가 인터로이킨 - 6인 사용방법.
  9. 제1항 내지 제8항중 어느 한항에 있어서, 상기 IL-6 분자가 하기 구조식(I)의 서열을 가지는 사용방법:
  10. 제8항에 있어서, 상기 IL-6 분자가 Ala-X(여기에서, X는 구조식(I)의 서열이다)인 사용방법.
  11. 제8항에 있어서, 상기 IL-6 분자가 Met-Ala-X(여기에서, X는 구조식(I)의 서열이다)인 사용방법.
  12. 제9항에 있어서, 상기 IL-6 분자에 하기의 서열이 첨가된 사용방법 : PRO VAL PRO PRO GLY GLU ASP SER LYS ASP VAL ALA ALA.
  13. 제1항에 있어서, 실시예중 어느 하나에 의거하여 전술한 바와같은 사용 방법.
  14. 제1항 내지 제7항에 언급된 질병중 하나를 치료하는 방법에 있어서, 상기 치료를 요하는 환자에게 제1항 내지 제13항중 어느 한항에 정의된 화합물을 투여하는 것으로 구성되는 방법.
  15. IL-6 분자를 함유하는 약학조성물과 제14항에 정의된 방법에 사용하기 위한 지시사항을 포함하는 팩.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019890002617A 1988-03-04 1989-03-03 Il-6 분자의 사용방법 KR890014124A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB888805231A GB8805231D0 (en) 1988-03-04 1988-03-04 Improvements in/relating to organic compounds
CH8805231 1988-03-04
CH8810899 1988-05-09
GB888810899A GB8810899D0 (en) 1988-05-09 1988-05-09 Improvements in/relating to organic compounds

Publications (1)

Publication Number Publication Date
KR890014124A true KR890014124A (ko) 1989-10-21

Family

ID=26293587

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890002617A KR890014124A (ko) 1988-03-04 1989-03-03 Il-6 분자의 사용방법

Country Status (17)

Country Link
EP (1) EP0331640A3 (ko)
JP (1) JPH01308234A (ko)
KR (1) KR890014124A (ko)
AU (1) AU621592B2 (ko)
BE (1) BE1003662A4 (ko)
CA (1) CA1332223C (ko)
CH (1) CH680070A5 (ko)
DE (1) DE3906923A1 (ko)
DK (1) DK102389A (ko)
FR (1) FR2628323B1 (ko)
GB (1) GB2216412B (ko)
HU (1) HUT52962A (ko)
IT (1) IT1230496B (ko)
NL (1) NL8900524A (ko)
PH (1) PH26238A (ko)
PT (1) PT89893A (ko)
SE (1) SE8900722L (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03197433A (ja) * 1989-12-26 1991-08-28 Otsuka Pharmaceut Co Ltd Ｉｌ―６産生誘導剤
IT1263022B (it) * 1992-11-06 1996-07-23 Angeletti P Ist Richerche Bio Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica.
GB9610281D0 (en) * 1996-05-16 1996-07-24 Ralston Stuart H Diagnostic method and apparatus
JP2001158736A (ja) * 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 骨関節疾患の予防及び改善剤
FI112031B (fi) * 2002-02-25 2003-10-31 Valio Oy Biologisesti aktiivisen tuotteen uusi käyttö
WO2004064762A2 (en) 2003-01-21 2004-08-05 S.S.C.I. Inc. Novel cocrystallization
DE602005020743D1 (de) * 2004-02-11 2010-06-02 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
GB0912159D0 (en) * 2009-07-14 2009-08-26 Imp Innovations Ltd Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE67035B1 (en) * 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
DE3750106T3 (de) * 1986-08-06 1999-04-22 Ajinomoto Kk Rekombinanter B-Zell-Differenzierungsfaktor.
US5271931A (en) * 1988-09-14 1993-12-21 The Scripps Research Institute Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6

Also Published As

Publication number Publication date
IT1230496B (it) 1991-10-24
DE3906923A1 (de) 1989-09-14
PT89893A (pt) 1989-11-10
GB8904646D0 (en) 1989-04-12
AU3094289A (en) 1989-09-07
CA1332223C (en) 1994-10-04
JPH01308234A (ja) 1989-12-12
BE1003662A4 (fr) 1992-05-19
SE8900722D0 (sv) 1989-03-02
DK102389A (da) 1989-09-05
NL8900524A (nl) 1989-10-02
EP0331640A3 (en) 1991-03-13
AU621592B2 (en) 1992-03-19
PH26238A (en) 1992-04-01
SE8900722L (sv) 1989-09-05
CH680070A5 (ko) 1992-06-15
DK102389D0 (da) 1989-03-02
EP0331640A2 (en) 1989-09-06
FR2628323B1 (fr) 1994-09-09
GB2216412A (en) 1989-10-11
FR2628323A1 (fr) 1989-09-15
HUT52962A (en) 1990-09-28
IT8947695A0 (it) 1989-03-01
GB2216412B (en) 1991-10-02

Similar Documents

Publication Publication Date Title
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE67505T1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE17079T1 (de) Praeparat zur behandlung von wunden der hautoberflaeche und verfahren zur herstellung des praeparats.
RU95106821A (ru) Циклопептиды, способ их получения, фармацевтическая композиция и способ ее получения
DE69914084D1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
ATE275419T1 (de) Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption
KR920004391A (ko) 치환된 카복실산의 코데인 염, 이의 제조방법, 이의 용도 및 약제학적 조성물
KR890014124A (ko) Il-6 분자의 사용방법
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
DE3880587T2 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
KR920700627A (ko) 치료제로서 1-페닐-2-아미노에탄올 유도체의 신규한 용도
SE8704436D0 (sv) Anvendning av antisekretoriska substanser for nya indikationer
KR890012942A (ko) 5-치환된 오르니틴 유도체
DE3676640D1 (de) Prazosin-pirbuterol-mischung zur bronchendilatation.
RU98101105A (ru) Новое применение в медицинских целях
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
KR950701216A (ko) 레마세미드의 파킨슨병 치료 용도(use of remacemide for the treatment of parkinson's disease)
FR2677650B1 (fr) Retinouides substitues par un cycle dithiane et leur utilisation, procede de preparation desdits composes, compositions cosmetique et pharmaceutique les contenant et utilisation therapeutique de cette derniere.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid